Has Jonathan Moses received payments from drug or device companies?

Yes. Drug and device makers reported $13,167 in general payments to Jonathan Moses across 46 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jonathan Moses did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jonathan Moses come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jonathan Moses

Pediatric Gastroenterology · Palo Alto, CANPI 1023254711

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $12,100 of the $13,167 with a category attached, or 91.9%. AbbVie accounts for 98.3% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $5,753 and has fallen 98.3% since, to $99 in 2025. Among pediatric gastroenterology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$13,167in general payments, 2019–2025

Across 46 payments — averaging $286.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$13K
Medtronic$86
Regeneron Healthcare Solutions, Inc.$37
Lilly USA, LLC$37
QOL Medical, LLC$31
Mirum Pharmaceuticals, Inc.$20
plus $19 from 1 others

$459,475in research payments, 2019–2025

Across 63 payments — averaging $7293.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Takeda Pharmaceuticals U.S.A., Inc.$157K
AbbVie$135K
Bristol Myers Squibb$52K
Janssen Research & Development, LLC$52K
Pfizer$32K
E.r. Squibb & Sons, L.L.C.$16K
plus $15K from 1 others

What the payments were for

Speaking & faculty fees$12,10092%
Food & beverage$1,0678%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	38	$12,938
Medtronic	1	$86
Regeneron Healthcare Solutions, Inc.	1	$37
Lilly USA, LLC	2	$37
QOL Medical, LLC	2	$31
Mirum Pharmaceuticals, Inc.	1	$20
Bristol Myers Squibb	1	$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Humira$5,616
Skyrizi$2,750
Rinvoq$1,100

How this compares

$13,167 in reported general payments places this provider in the 90th percentile of 220 pediatric gastroenterology providers in California.

See all pediatric gastroenterology providers in California →

Other pediatric gastroenterology in Palo Alto

Michael RosenPalo Alto$27K
Helen John-KellyPalo Alto$8K
Roberto GugigPalo Alto$8K
Shweta NamjoshiPalo Alto$8K
John KernerPalo Alto$6K
Shikib MostamandPalo Alto$3K
Hilary JerichoPalo Alto$3K
David ZiringLos Angeles$206K
Nathan MinkoffMadera$131K
Paul HarmatzOakland$109K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →